GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Response Genetics Inc (OTCPK:RGDXQ) » Definitions » Beneish M-Score

Response Genetics (Response Genetics) Beneish M-Score : 0.00 (As of Jun. 20, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Response Genetics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Response Genetics's Beneish M-Score or its related term are showing as below:

During the past 11 years, the highest Beneish M-Score of Response Genetics was 0.00. The lowest was 0.00. And the median was 0.00.


Response Genetics Beneish M-Score Historical Data

The historical data trend for Response Genetics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Response Genetics Beneish M-Score Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.57 -2.72 -2.40 -

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.32 -3.49 -2.40 -3.51 -

Competitive Comparison of Response Genetics's Beneish M-Score

For the Diagnostics & Research subindustry, Response Genetics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Response Genetics's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Response Genetics's Beneish M-Score falls into.



Response Genetics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Response Genetics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5299+0.528 * 0.0598+0.404 * 1.3063+0.892 * 2.0682+0.115 * 0.4635
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9135+4.679 * -0.617183-0.327 * 3.2594
=-6.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar15) TTM:Last Year (Mar14) TTM:
Total Receivables was $6.06 Mil.
Revenue was 3.791 + -2.442 + 4.465 + 4.281 = $10.10 Mil.
Gross Profit was 1.476 + -3.328 + 1.922 + 1.695 = $1.77 Mil.
Total Current Assets was $8.76 Mil.
Total Assets was $10.78 Mil.
Property, Plant and Equipment(Net PPE) was $1.27 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.82 Mil.
Selling, General, & Admin. Expense(SGA) was $16.72 Mil.
Total Current Liabilities was $4.88 Mil.
Long-Term Debt & Capital Lease Obligation was $10.84 Mil.
Net Income was -4.018 + -6.356 + -3.644 + -3.139 = $-17.16 Mil.
Non Operating Income was 0 + 0.656 + -0.03 + -0.008 = $0.62 Mil.
Cash Flow from Operations was -1.88 + -1.757 + -4.302 + -3.184 = $-11.12 Mil.
Total Receivables was $5.53 Mil.
Revenue was 3.895 + -8.42 + 4.092 + 5.314 = $4.88 Mil.
Gross Profit was 1.457 + -5.364 + 1.352 + 2.606 = $0.05 Mil.
Total Current Assets was $11.82 Mil.
Total Assets was $14.36 Mil.
Property, Plant and Equipment(Net PPE) was $1.77 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.40 Mil.
Selling, General, & Admin. Expense(SGA) was $8.85 Mil.
Total Current Liabilities was $6.31 Mil.
Long-Term Debt & Capital Lease Obligation was $0.12 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(6.059 / 10.095) / (5.529 / 4.881)
=0.600198 / 1.13276
=0.5299

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.051 / 4.881) / (1.765 / 10.095)
=0.010449 / 0.174839
=0.0598

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (8.756 + 1.265) / 10.778) / (1 - (11.819 + 1.767) / 14.358)
=0.070236 / 0.053768
=1.3063

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=10.095 / 4.881
=2.0682

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.395 / (0.395 + 1.767)) / (0.823 / (0.823 + 1.265))
=0.182701 / 0.394157
=0.4635

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(16.715 / 10.095) / (8.847 / 4.881)
=1.65577 / 1.812538
=0.9135

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((10.838 + 4.877) / 10.778) / ((0.116 + 6.307) / 14.358)
=1.458063 / 0.447346
=3.2594

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-17.157 - 0.618 - -11.123) / 10.778
=-0.617183

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Response Genetics has a M-score of -6.01 suggests that the company is unlikely to be a manipulator.


Response Genetics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Response Genetics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Response Genetics (Response Genetics) Business Description

Traded in Other Exchanges
N/A
Address
201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.
Executives
Roberto Mignone 10 percent owner C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016
Bridger Management Llc 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Swiftcurrent Offshore Ltd 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
David Schreiber director 15 TROTTERS LANE, MONROE CT 06468
Sam Chawla director 1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Kevin Roy Harris officer: Vice President and CFO 345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210
Kirk K Calhoun director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael Serruya director C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033
Thomas A Bologna director, officer: Chief Executive Officer 4390 US ROUTE ONE, PRINCETON NJ 08540
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Partners Swiftcurrent 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Bridger Capital Llc 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A Metzger director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451

Response Genetics (Response Genetics) Headlines

From GuruFocus

Response Genetics Inc. (RGDX) CFO Thomas Stankovich buys 7,000 Shares

By GuruFocus Research GuruFocus Editor 12-14-2009